ADVERTORIAL
Analytical insight across the development pathway
Analytical science sits at the centre of successful integration. It provides the evidence required to understand a molecule, control a process, demonstrate quality and support regulatory progression.
Almac’ s analytical expertise spans drug substance and drug product development, enabling a joined-up understanding of critical quality attributes from raw materials through to finished product. This includes method development, validation, stability testing, impurity identification, solid-state characterisation and release testing.
For integrated programmes, a connected analytical strategy helps avoid duplication, reduces the risk of method transfer issues and ensures that data generated at each stage supports the next.
This is especially relevant for complex molecules, difficult-to-analyse compounds or products requiring specialised analytical techniques. By applying analytical insight across both drug substance and drug product workstreams, Almac helps clients build a clearer picture of product performance, process control and long-term developability.
A connected path from API to finished product
Once a suitable API route and control strategy are established, the next challenge is translating that material into a finished product that can be manufactured, packaged, supplied and administered effectively.
Almac provides drug product development and manufacturing capabilities, including formulation development, clinical trial material manufacture, packaging, labelling and supply chain solutions. When combined with our API expertise, clients benefit from a more seamless transition between drug substance and drug product activities.
This integrated approach can help address practical questions earlier. Is the API suitable for the intended formulation? Are there stability or compatibility concerns? Do particle attributes need tighter control? Are analytical methods suitable for both API and finished product release? Can development batches be aligned with clinical supply timelines?
By considering these questions across disciplines, Almac helps clients reduce handover risk and improve programme efficiency.
Serious science, delivered practically
Almac’ s approach reflects a simple principle: difficult science requires joined-up thinking. While every development programme is different, complex molecules often demand more than standard solutions. They require experience, technical judgement and the ability to bring the right expertise together at the right time.
In the context of integrated drug substance and drug product development, it is not about complexity for its own sake. It is about applying scientific depth, practical experience and disciplined execution to help clients overcome barriers that could otherwise slow or compromise development.
Combined with Almac Pharma Services, this creates a broader service platform that can support clients across API development, RSM and intermediate supply, drug product development, clinical supply and commercialisation.
Reducing complexity for clients
Pharmaceutical development will always involve uncertainty. However, the way programmes are structured can either increase or reduce that uncertainty. An integrated partner can help simplify the development journey by improving communication, aligning scientific decisions and reducing the number of interfaces a client must manage. This does not remove the need for specialist expertise. Instead, it ensures that specialist expertise is connected, coordinated and focused on the same end goal.
For clients developing challenging molecules, this can mean faster issue resolution, better-informed decisions and a clearer path through development. It can also support stronger regulatory narratives, as data and rationale are generated through a more cohesive scientific strategy.
From molecule to medicine
Bringing a new medicine to patients requires more than technical capability. It requires collaboration, foresight and a practical understanding of how decisions made early in development shape outcomes later.
Through the combined strengths of Almac’ s drug substance and drug product teams, we offer clients an integrated pathway from complex drug substance development through to finished drug product supply. With expertise spanning RSMs, intermediates, APIs, formulation, analytical testing, manufacturing and clinical supply, Almac is well positioned to support programmes where scientific challenge, speed and quality all matter.
For organisations seeking to progress complex molecules with confidence, this integrated approach offers a clear advantage: one connected partner, combining serious scientific depth with the practical capability to move promising compounds closer to patients. ●
CPHI stand 6A28 | info @ almacgroup. com
SEP / OCT 2026 SPECCHEMONLINE. COM
67